Overview

Pharmacokinetics and Dynamics of Dexmedetomidine as Adjuvant in TAP Block

Status:
Completed
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
TAP-block has been shown to be a safe and effective postoperative analgesia method in a variety of general. Dexmedetomidine is a selective α2 agonist with 8 times more affinity for α2 adrenergic receptors compared to clonidine and possesses all the properties of α2 agonist without respiratory depression. Dexmedetomidine has been focus of interest for its broad spectrum (sedative, analgesic and anesthetic sparing) properties, making it a useful and safe adjunct in many clinical applications.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Assiut University
Treatments:
Bupivacaine
Dexmedetomidine